Table 1.
Baseline demographics
| Missing | Overall (n = 144) | Residual (n = 94) | pCR (n = 50) | p-Value | |
|---|---|---|---|---|---|
| Age at Diagnosis, mean (SD) | 0 | 51.7 (12.7) | 51.4 (12.5) | 52.3 (13.3) | 0.71 |
| Race, n (%) | |||||
| African American | 6 | 72 (50.0) | 50 (53.2) | 22 (44.0) | 0.22 |
| Asian | 4 (2.8) | 4 (4.3) | |||
| Caucasian | 51 (35.4) | 28 (29.8) | 23 (46.0) | ||
| Native American | 1 (0.7) | 1 (1.1) | |||
| Other / Missing | 16 (11.1) | 11 (11.7) | 5(10.0) | ||
| Histology, n (%) | |||||
| Adenocarcinoma | 0 | 1 (0.7) | 0 (0.0) | 1 (2.0) | 0.21 |
| Invasive Ductal Carcinoma | 138 (95.8) | 89 (94.7) | 49 (98.0) | ||
| Invasive Lobular Carcinoma | 4 (2.8) | 4 (4.3) | 0 (0.0) | ||
| Metaplastic Carcinoma | 1 (0.7) | 1 (1.1) | 0 (0.0) | ||
| Receptor Status n (%) | |||||
| HR + /HER2 + | 0 | 24 (16.7) | 19 (20.2) | 5 (10.0) | < 0.001 |
| HR + /HER2- | 36 (25.0) | 31 (33.0) | 5 (10.0) | ||
| HR−/HER2 + | 25 (17.4) | 7 (7.4) | 18 (36.0) | ||
| TNBC | 59 (41.0) | 37 (39.4) | 22 (44.0) | ||
| Grade, n (%) | |||||
| 1 | 0 | 2 (1.4) | 2 (2.1) | 0.14 | |
| 2 | 31 (21.5) | 24 (25.5) | 7 (14.0) | ||
| 3 | 111 (77.1) | 68 (72.3) | 43 (86.0) | ||
| Tumor Stage, n (%) | |||||
| T1 | 0 | 27 (18.8) | 17 (18.1) | 10 (20.0) | 0.24 |
| T2 | 86 (59.7) | 52 (55.3) | 34 (68.0) | ||
| T3 | 27 (18.8) | 22 (23.4) | 5 (10.0) | ||
| T4 | 4 (2.8) | 3 (3.2) | 1 (2.0) | ||
| Nodal Stage, n (%) | |||||
| N0 | 0 | 72 (50.0) | 43 (45.7) | 29 (58.0) | 0.57 |
| N1 | 59 (41.0) | 42 (44.7) | 17 (34.0) | ||
| N2 | 10 (6.9) | 7 (7.4) | 3 (6.0) | ||
| N3 | 3 (2.1) | 2 (2.1) | 1 (2.0) | ||
| Regimen, n (%) | |||||
| HER2-directed, Anthracycline containing | 0 | 19 (13.2) | 11 (11.7) | 8 (16.0) | 0.41 |
| HER2-directed, Anthracycline free | 35 (24.3) | 20 (21.3) | 15 (30.0) | ||
| Chemotherapy, Anthracycline free | 6 (4.2) | 5 (5.3) | 1 (2.0) | ||
| Chemotherapy, Anthracycline containing | 84 (58.3) | 58 (61.7) | 26 (52.0) | ||
| Months Follow-up, mean (SD) | 0 | 5.6 (2.7) | 5.3 (2.7) | 5.9 (2.7) | 0.21 |
| Alive, n (%) | |||||
| Yes | 0 | 123 (85.4) | 76 (80.9) | 47 (94.0) | 0.06 |
| No | 21 (14.6) | 18 (19.1) | 3 (6.0) | ||
| Recurrence, n (%) | |||||
| Yes | 0 | 16 (11.1) | 16 (17.0) | 0.005 | |
| No | 128 (88.9) | 78 (83.0) | 50 (100.0) |
p values for comparison between cases with pCR and residual disease
Statistics are listed on a per-tumor level, with three cases of bilateral breast cancer
pCR Pathologic complete response (ypT0N0 or ypTisN0), HR Hormone receptor, HER2 Human epidermal growth factor receptor 2, TNBC Triple-negative breast cancer